Germany's Merz pleased to find broad agreement with Macron in Paris
Germany's presumptive next chancellor, Friedrich Merz, described his three-hour meeting with French President Emmanuel Macron in Paris on Wednesday as a great success, in which the two leaders found broad agreement.
"The similarities were even greater than I had expected," Merz, a centre-right Christian Democrat (CDU), told the Frankfurter Allgemeine newspaper in remarks published on Thursday.
Macron and Merz had both declared their intention to open a new chapter in Franco-German relations after their working dinner date at the Élysée Palace.
Observers had widely speculated that Macron had a frosty relationship with outgoing German Chancellor Olaf Scholz.
The Paris visit was Merz's first trip abroad since his CDU and its Bavarian sister party, the Christian Social Union (CSU), placed first in Sunday's national election.
Macron has not spoken publicly about what the two men discussed in their meeting, but the Frankfurter Allgemeine reported that the exchange covered all topics from defence to migration to trade policy and was extremely constructive.
Merz described the atmosphere of the talks as cordial, trusting and inspired by their mutual desire to make rapid progress in the face of major geopolitical challenges facing both countries.
After the meeting, Merz wrote in a post on X in both German and French: "Thank you, dear [Emmanuel Macron], for your friendship and your trust in Franco-German relations. Together, our countries can achieve great things for Europe."
Merz speaks French and has a close relationship with France. As a teenager, Merz was on a school exchange programme in Auvergne, and he and his family also spent several holidays in France.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
2 hours ago
- San Francisco Chronicle
Photos: Bing Crosby's historic California estate sells for $25 million
A historic Hillsborough estate once owned by Bing Crosby has sold for $25 million, more than a third below its original asking price but still one of the most expensive residential sales in the town's history. The property at 1200 Jackling Drive, a 14,000-square-foot French chateau-style mansion on 5 acres, was listed in January for $40 million following the death of Crosby's widow, Kathryn Grant, in 2024. The deal closed Thursday, June 12, according to Compass agents Alex and Pierre Buljan, who represented the buyer. 'This property is one of Hillsborough's legacy estates with an extremely storied background and impeccable vintage craftsmanship,' Alex Buljan said in a statement. 'The buyer is a Hillsborough local with an appreciation for classic properties, adamant about maintaining the character and history into the next generation.' Originally built in 1929 for the Howard family, owners of the racehorse Seabiscuit, the home was purchased by Crosby in the 1960s as a retreat from Hollywood. The singer lived there until he died in 1977, and the estate remained in the family until this year. The mansion includes 11 bedrooms, a library, a smoking room and a staff wing. Architectural features include antique paneling and a 17th century staircase acquired by the Howards from William Randolph Hearst's collection. 'If the product that a buyer is looking for is there, it is going fast,' she said. The sale is Hillsborough's highest-priced residential deal since the Western White House sold for $23 million last year, and ranks among the top five in the town's history.
Miami Herald
3 hours ago
- Miami Herald
See the opulent Bing Crosby estate in Bay Area. It just sold for $25 million
The Bay Area estate Bing Crosby purchased in the early 1960s as a surprise for his wife Kathryn sold Thursday, June 12, for $25 million, according to Compass real estate. 'This property is one of Hillsborough's legacy estates with an extremely storied background and impeccable vintage craftsmanship,' Compass listing agent Alex Buljan said in a statement. 'The buyer is a Hillsborough local with an appreciation for classic properties, adamant about maintaining the character and history into the next generation.' Hillsborough is a wealthy town in San Mateo County, 20 miles south of San Francisco, California. The 16,600-square-foot Bing Crosby Estate was listed for $40 million earlier this year after the late singer's second wife died in 2024. The property is one of the top five sales in the history of Hillsborough, and largest since the Western White House closed for $23 million last year. Buljan also represented the buyer on that home. Crosby purchased the estate in the early 1960s as an escape for his family from the Hollywood scene. The eye-catching French chateau-style residence, built in 1929, sits on 5.4 acres. In a blend of history and elegance, businessman Lindsay Howard, son of horse-racing enthusiast and Seabiscuit owner Charles Howard, originally commissioned the estate to be built by architects John Bakewell Jr. and Ernest Weihe as a wedding gift for his wife Anita. The Crosbys moved into the residence in December 1965 with their children, Harry Lillis Jr., Nathaniel and Mary Frances and embarked on extensive renovations, according to Sotheby's. The couple incorporated antiques from William Randolph Hearst's collection, including a hand-carved wooden staircase banister and Georgian paneling from a 17th-century English manor home. Then, Kathryn Crosby commissioned renowned San Francisco artist Al Proom to decorate the dining room walls, adding more grandeur to the home. This estate — with 11 bedrooms, 10 full bathrooms and 5 half bathrooms — has meticulously preserved craftsmanship and architectural details from the 1920s design. The opulent home is highlighted with frescoes, ornate fireplaces and hand-carved woodwork. A smoking room contains a built-in bar. The library beckons with a large fireplace and built-in bookcases. In the dining room, a Venetian-glass chandelier hangs and hand-painted rose detailing adorns the walls. There's a separate wing for staff.
Yahoo
3 hours ago
- Yahoo
BioNTech buys mRNA, courtroom rival CureVac in all-stock deal
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. COVID vaccine maker BioNTech is buying rival CureVac, announcing Thursday an all-stock deal weeks before the two companies were due to face off in a German court over potentially billions of dollars worth of royalties related to intellectual property on messenger RNA drugs. Per deal terms, each CureVac share will be exchanged for about $5.46 worth of BioNTech's U.S.-listed shares, valuing the company at $1.25 billion. Upon the deal's close, CureVac shareholders will own between 4% and 6% of BioNTech. In the early days of the COVID-19 pandemic, BioNTech and CureVac were among the companies racing to develop the first coronavirus vaccines. BioNTech, however, partnered with Pfizer and won approval of the first COVID-19 shot, while CureVac's program never made it to market. The two companies have since been embroiled in patent litigation. CureVac was a leading candidate to develop the first COVID-19 vaccine, launching rumors, later denied, that the U.S. government might even buy the company or its research. But while BioNTech and fellow mRNA drugmaker Moderna succeeded in making vaccines that saved millions of lives and earned billions of dollars in revenue, CureVac fell short. Its initial project wasn't effective enough at preventing sickness, prompting it to scrap development. A year later, CureVac sued BioNTech, claiming it infringed four patents. CureVac has since changed course, selling off most rights to influenza and COVID-19 vaccines to partner GSK and focusing on cancer instead. But its legal spat with BioNTech has lingered. The European Patent Office had upheld two CureVac patents, and a trial in a Dusseldorf regional court was set on July 1 to determine if BioNTech had infringed on them. A separate trial in the U.S. was scheduled to begin Sept. 8 in Virginia. Some Wall Street analysts, as a result, speculated that BioNTech's primary purpose is buying CureVac is to sidestep the risk of a loss in court. A single-digit percentage royalty awarded to CureVac could've cost BioNTech as much as $3 billion, Evercore ISI analyst Umer Raffat wrote in a note to clients. 'It seems to us that [BioNTech] assessed the cost of a cash settlement as substantially greater than the cost of buying [CureVac] outright,' Raffat wrote. The deal could also help BioNTech further its oncology ambitions. Like CureVac, BioNTech has made cancer research a top priority. It's invested in a variety of programs, from cell therapies to mRNA vaccines and a coveted type of bispecific antibody. Some are in advanced testing. CureVac's cancer vaccines are in earlier phases of development. A brain cancer shot has delivered early clinical data, while a lung cancer immunotherapy was cleared in April for human testing. The deal should help CureVac because of 'the early stage of the oncology pipeline and the need for a development partner to effectively compete in personalized cancer vaccines – which [BioNTech] is well positioned to execute,' wrote Leerink Partners analyst Mani Foroohar. Raffat, of Evercore ISI, however, wrote that the deal ascribes 'very little value' to CureVac's pipeline. Recommended Reading Recursion to acquire two Canadian drug discovery startups Sign in to access your portfolio
